Ketamine Therapy
Ketamine Therapy
As part of our mission to help NJ residents improve their mental health, the expert medical staff at Princeton Medical Institute has made ketamine treatment available to our patients. Much research has been conducted on the treatment of major depression and other mental health issues using ketamine. This revolutionary treatment is now more accessible than ever and can help patients that have found their conditions to be previously treatment-resistant. Ketamine – which may be administered nasally or intravenously – is a fast-acting alternative to traditional antidepressant medications that also lacks most of the associated side effects.
What can ketamine therapy treat?
Our Princeton, NJ site is currently enrolling subjects with a variety of conditions into research studies. Our studies seek to determine the safety and efficacy of an investigatory drug for the treatment of those with the disease. All study related visits, laboratory work, medications, and procedures – including physical exams – are provided at no cost to those who qualify for the study. Qualified participants will receive compensation for time and travel. Other criteria for eligibility will be discussed with interested persons, without obligation.
How does ketamine therapy work?
Ketamine was first used in a medical context as a surgical anesthetic over 50 years ago. Since then, its applications for treating mental health and chronic pain have become evident. Traditional antidepressants target the serotonin and noradrenaline systems of the brain. In contrast, ketamine blocks N-myethyl-D-aspartate (NDMA), a receptor in the brain activated by a neurotransmitter called glutamate. In the process, it repairs damage in the brain’s synapses.
More Information
Over 70% of patients who get ketamine treatment show a response – often after the very first session. Ketamine therapy may be administered in two different ways: intravenously or nasally. While intravenous ketamine has not been approved by the FDA to treat depression, the American Psychiatric Association has endorsed its off-label use, attesting to its safety and effectiveness. On the other hand, nasal ketamine treatment – known as Spravato – is approved by the FDA for treatment-resistant depression.
